Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here

Request a Proposal  

Ventilator-Associated Pneumonia Case Study

As the most common healthcare-related infection in intensive care units, and one of the most dreaded complications of in-hospital care, ventilator-associated pneumonia (VAP) is a cause for serious concern and demands meticulous care efforts to be taken. Pharm-Olam is proud to be partnering with a progressive drug development company in their search for a solution when a VAP diagnosis is made.

Study Overview:

A Phase III study for the treatment of ventilator-associated pneumonia (VAP) in intensive care patients.

Sites & Locations:

120+ Sites across 25 countries in Asia, Eastern and Western Europe, and the Middle East

Services Provided:

  • Site Identification & Selection
  • Regulatory
  • Clinical & Medical Monitoring
  • Project Management
  • Quality Assurance

Learn the details by clicking on the image on the right.